Loading...
Low-Dose Mepolizumab Effectiveness in Patients Suffering From Eosinophilic Granulomatosis With Polyangiitis
Eosinophilic granulomatosis with polyangiitis (EGPA) is a vasculitis characterized by multisystemic manifestations including asthma. Mepolizumab (300 mg/4 weeks) has recently been approved for EGPA. However, real-life data are scarce and report experiences with high doses of mepolizumab intravenousl...
Na minha lista:
| Udgivet i: | Allergy Asthma Immunol Res |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
The Korean Academy of Asthma, Allergy and Clinical Immunology; The Korean Academy of Pediatric Allergy and Respiratory Disease
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7346991/ https://ncbi.nlm.nih.gov/pubmed/32638567 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4168/aair.2020.12.5.885 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|